- $19 million of series 2017A revenue bonds
- $86 million of series 2017C revenue bonds
The rating affirmations are based on a number of factors, including the cancer center’s national standing as a leading research institute, strong unrestricted liquidity and strong fundraising capabilities.
The outlook is stable, reflecting Moody’s Investors Service’s expectation the cancer center will improve its liquidity supporting debt and operations, its growing research activity and positive operating cash flow generation for adequate debt service.
More articles on healthcare finance:
S&P places MetroHealth System’s ‘A-‘ bonds on CreditWatch
S&P lowers North Oaks Health System’s rating to ‘BB+’ on select bonds
Fitch assigns ‘AA-‘ rating to University Medical Center of El Paso’s bonds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
